Prospects for the treatment of Parkinson's disease using neural grafts.
Parkinson's disease (PD) is an incurable neurodegenerative condition of the central nervous system (CNS) that typically presents in the fifth to seventh decade of life, with a movement disorder that consists of a resting tremor, bradykinesia and rigidity. It is a disease that can only be diagnosed with certainty at postmortem when the pathological hallmark is loss of the dopaminergic nigrostriatal pathway and presence of Lewy bodies in the substantia nigra. However, pathological changes, including Lewy body formation, are found outside of the nigrostriatal system and involve other neurotransmitters, which may also account for some of the cognitive, psychiatric and autonomic abnormalities in these patients. To date, the mainstay of treatment for patients with PD has been drugs that activate the dopaminergic network, namely the dopamine precursor L-dopa and dopamine receptor agonists. However, recently interest has turned towards more curative therapies, including the use of grafts of neural tissue to replace dopaminergic neurones that have been lost. This approach has now entered clinical trials and this review will analyse the therapeutic approach of neural grafting in PD.
Cambridge Centre for Brain Repair and Department of Neurology, Addenbrooke's Hospital, Cambridge CB2 2PY, UK. rab46@cus.cam.ac.uk
R A
RA
Barker
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D016380:Brain Tissue Transplantation; D004298:Dopamine / Q000502:physiology; D016332:Fetal Tissue Transplantation; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery*; D013378:Substantia Nigra / Q000637:transplantation
D000978:Antiparkinson Agents; D004298:Dopamine